Free Trial
Memorial Day Savings! Save $100 on MarketBeat All Access
Claim Your Discount
Claim MarketBeat All Access Sale Promotion

Oxford Biomedica (OXB) Competitors

Oxford Biomedica logo
GBX 611 +2.00 (+0.33%)
As of 06:54 AM Eastern
Compare

OXB vs. ABC, GNS, ONT, ERGO, and SLN

Should you buy Oxford Biomedica stock or one of its competitors? MarketBeat compares Oxford Biomedica with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oxford Biomedica include Abcam (ABC), Genus (GNS), Oxford Nanopore Technologies (ONT), Ergomed (ERGO), and Silence Therapeutics (SLN). These companies are all part of the "biotechnology" industry.

How does Oxford Biomedica compare to Abcam?

Abcam (LON:ABC) and Oxford Biomedica (LON:OXB) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

Abcam has higher revenue and earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Abcam, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abcam£350.40M0.00N/A£0.06N/A
Oxford Biomedica£168.74M4.34-£143.51M-£26.92N/A

Oxford Biomedica has a consensus target price of GBX 687, suggesting a potential upside of 13.37%. Given Oxford Biomedica's stronger consensus rating and higher possible upside, analysts plainly believe Oxford Biomedica is more favorable than Abcam.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abcam
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Oxford Biomedica
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86

Abcam has a net margin of 0.00% compared to Oxford Biomedica's net margin of -17.85%. Abcam's return on equity of 0.00% beat Oxford Biomedica's return on equity.

Company Net Margins Return on Equity Return on Assets
AbcamN/A N/A N/A
Oxford Biomedica -17.85%-48.56%-12.67%

In the previous week, Abcam's average media sentiment score of 0.00 equaled Oxford Biomedica'saverage media sentiment score.

Company Overall Sentiment
Abcam Neutral
Oxford Biomedica Neutral

32.4% of Oxford Biomedica shares are held by institutional investors. 25.9% of Oxford Biomedica shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Abcam beats Oxford Biomedica on 6 of the 11 factors compared between the two stocks.

How does Oxford Biomedica compare to Genus?

Genus (LON:GNS) and Oxford Biomedica (LON:OXB) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

Genus has a beta of 0.895, indicating that its stock price is 11% less volatile than the broader market. Comparatively, Oxford Biomedica has a beta of 1.095, indicating that its stock price is 10% more volatile than the broader market.

53.1% of Genus shares are owned by institutional investors. Comparatively, 32.4% of Oxford Biomedica shares are owned by institutional investors. 0.7% of Genus shares are owned by insiders. Comparatively, 25.9% of Oxford Biomedica shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Genus has higher revenue and earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genus£672M2.34£7.87M£71.0033.38
Oxford Biomedica£168.74M4.34-£143.51M-£26.92N/A

In the previous week, Genus had 4 more articles in the media than Oxford Biomedica. MarketBeat recorded 4 mentions for Genus and 0 mentions for Oxford Biomedica. Genus' average media sentiment score of 0.36 beat Oxford Biomedica's score of 0.00 indicating that Genus is being referred to more favorably in the media.

Company Overall Sentiment
Genus Neutral
Oxford Biomedica Neutral

Genus presently has a consensus price target of GBX 3,216.67, indicating a potential upside of 35.72%. Oxford Biomedica has a consensus price target of GBX 687, indicating a potential upside of 13.37%. Given Genus' stronger consensus rating and higher probable upside, equities analysts clearly believe Genus is more favorable than Oxford Biomedica.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genus
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Oxford Biomedica
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86

Genus has a net margin of 7.07% compared to Oxford Biomedica's net margin of -17.85%. Genus' return on equity of 9.70% beat Oxford Biomedica's return on equity.

Company Net Margins Return on Equity Return on Assets
Genus7.07% 9.70% 3.31%
Oxford Biomedica -17.85%-48.56%-12.67%

Summary

Genus beats Oxford Biomedica on 12 of the 16 factors compared between the two stocks.

How does Oxford Biomedica compare to Oxford Nanopore Technologies?

Oxford Nanopore Technologies (LON:ONT) and Oxford Biomedica (LON:OXB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Oxford Biomedica has lower revenue, but higher earnings than Oxford Nanopore Technologies. Oxford Biomedica is trading at a lower price-to-earnings ratio than Oxford Nanopore Technologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford Nanopore Technologies£223.90M5.32-£175.21M-£15.10N/A
Oxford Biomedica£168.74M4.34-£143.51M-£26.92N/A

18.9% of Oxford Nanopore Technologies shares are owned by institutional investors. Comparatively, 32.4% of Oxford Biomedica shares are owned by institutional investors. 2.3% of Oxford Nanopore Technologies shares are owned by company insiders. Comparatively, 25.9% of Oxford Biomedica shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Oxford Nanopore Technologies currently has a consensus price target of GBX 218.60, suggesting a potential upside of 78.59%. Oxford Biomedica has a consensus price target of GBX 687, suggesting a potential upside of 13.37%. Given Oxford Nanopore Technologies' higher possible upside, equities research analysts clearly believe Oxford Nanopore Technologies is more favorable than Oxford Biomedica.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oxford Nanopore Technologies
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80
Oxford Biomedica
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86

In the previous week, Oxford Nanopore Technologies had 5 more articles in the media than Oxford Biomedica. MarketBeat recorded 5 mentions for Oxford Nanopore Technologies and 0 mentions for Oxford Biomedica. Oxford Nanopore Technologies' average media sentiment score of 1.33 beat Oxford Biomedica's score of 0.00 indicating that Oxford Nanopore Technologies is being referred to more favorably in the media.

Company Overall Sentiment
Oxford Nanopore Technologies Positive
Oxford Biomedica Neutral

Oxford Nanopore Technologies has a beta of 0.869, meaning that its share price is 13% less volatile than the broader market. Comparatively, Oxford Biomedica has a beta of 1.095, meaning that its share price is 10% more volatile than the broader market.

Oxford Biomedica has a net margin of -17.85% compared to Oxford Nanopore Technologies' net margin of -64.85%. Oxford Nanopore Technologies' return on equity of -29.43% beat Oxford Biomedica's return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford Nanopore Technologies-64.85% -29.43% -14.42%
Oxford Biomedica -17.85%-48.56%-12.67%

Summary

Oxford Nanopore Technologies and Oxford Biomedica tied by winning 8 of the 16 factors compared between the two stocks.

How does Oxford Biomedica compare to Ergomed?

Oxford Biomedica (LON:OXB) and Ergomed (LON:ERGO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

32.4% of Oxford Biomedica shares are held by institutional investors. Comparatively, 71.1% of Ergomed shares are held by institutional investors. 25.9% of Oxford Biomedica shares are held by company insiders. Comparatively, 18.2% of Ergomed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Oxford Biomedica presently has a consensus target price of GBX 687, suggesting a potential upside of 13.37%. Given Oxford Biomedica's stronger consensus rating and higher probable upside, equities analysts clearly believe Oxford Biomedica is more favorable than Ergomed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oxford Biomedica
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86
Ergomed
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Oxford Biomedica's average media sentiment score of 0.00 equaled Ergomed'saverage media sentiment score.

Company Overall Sentiment
Oxford Biomedica Neutral
Ergomed Neutral

Ergomed has lower revenue, but higher earnings than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oxford Biomedica£168.74M4.34-£143.51M-£26.92N/A
Ergomed£152.09M0.00£15M£0.29N/A

Oxford Biomedica has a beta of 1.095, suggesting that its share price is 10% more volatile than the broader market. Comparatively, Ergomed has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market.

Ergomed has a net margin of 9.87% compared to Oxford Biomedica's net margin of -17.85%. Ergomed's return on equity of 18.08% beat Oxford Biomedica's return on equity.

Company Net Margins Return on Equity Return on Assets
Oxford Biomedica-17.85% -48.56% -12.67%
Ergomed 9.87%18.08%10.16%

Summary

Ergomed beats Oxford Biomedica on 7 of the 13 factors compared between the two stocks.

How does Oxford Biomedica compare to Silence Therapeutics?

Silence Therapeutics (LON:SLN) and Oxford Biomedica (LON:OXB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

Silence Therapeutics has a net margin of 0.00% compared to Oxford Biomedica's net margin of -17.85%. Silence Therapeutics' return on equity of 0.00% beat Oxford Biomedica's return on equity.

Company Net Margins Return on Equity Return on Assets
Silence TherapeuticsN/A N/A N/A
Oxford Biomedica -17.85%-48.56%-12.67%

Silence Therapeutics has higher earnings, but lower revenue than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silence Therapeutics£11.35M0.00N/A-£48.60N/A
Oxford Biomedica£168.74M4.34-£143.51M-£26.92N/A

In the previous week, Silence Therapeutics' average media sentiment score of 0.00 equaled Oxford Biomedica'saverage media sentiment score.

Company Overall Sentiment
Silence Therapeutics Neutral
Oxford Biomedica Neutral

Oxford Biomedica has a consensus target price of GBX 687, indicating a potential upside of 13.37%. Given Oxford Biomedica's stronger consensus rating and higher possible upside, analysts clearly believe Oxford Biomedica is more favorable than Silence Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Silence Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Oxford Biomedica
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86

32.4% of Oxford Biomedica shares are held by institutional investors. 25.9% of Oxford Biomedica shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Oxford Biomedica beats Silence Therapeutics on 7 of the 11 factors compared between the two stocks.

Get Oxford Biomedica News Delivered to You Automatically

Sign up to receive the latest news and ratings for OXB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OXB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OXB vs. The Competition

Export
MetricOxford BiomedicaBiotechnology IndustryMedical SectorLON Exchange
Market Cap£732.77M£461.76M£6.25B£2.77B
Dividend Yield4.57%3.86%2.80%6.15%
P/E Ratio-22.513.8620.63366.05
Price / Sales4.347,594.42554.9387,894.60
Price / Cash3.0113.1327.4827.89
Price / Book8.9583.469.697.65
Net Income-£143.51M-£96.07M£3.56B£5.89B
7 Day Performance-4.57%0.43%-1.63%0.72%
1 Month Performance-5.46%-0.26%-2.59%0.85%
1 Year Performance103.36%69.16%30.08%84.33%

Oxford Biomedica Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OXB
Oxford Biomedica
N/AGBX 611
+0.3%		GBX 687
+12.4%		+101.7%£738.82M£168.74MN/A891
ABC
Abcam
N/AN/AN/AN/A£2.81B£350.40M20,433.331,650
GNS
Genus
3.4212 of 5 stars		GBX 2,328
+1.8%		GBX 3,216.67
+38.2%		+12.8%£1.55B£672M32.79480
ONT
Oxford Nanopore Technologies
2.6663 of 5 stars		GBX 120.70
+0.2%		GBX 218.60
+81.1%		-7.0%£1.17B£223.90MN/A1,281
ERGO
Ergomed
N/AN/AN/AN/A£701.00M£152.09M4,641.386

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:OXB) was last updated on 5/19/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...
Weiss Ratings | Sponsoredtc pixel